# Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

> **NCT03343639** · PHASE2 · COMPLETED · sponsor: **Vyne Therapeutics Inc.** · enrollment: 204 (actual)

## Conditions studied

- Pruritus
- Psoriasis

## Interventions

- **DRUG:** 5 mg Serlopitant Tablets
- **DRUG:** Matching Placebo Tablets

## Key facts

- **NCT ID:** NCT03343639
- **Lead sponsor:** Vyne Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2018-10-23
- **Final completion:** 2018-11-12
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03343639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03343639, "Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03343639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*